Analysis Alligator: Presumed capital raise for phase 2

Ever since Alligator received Mitazalimab back from Janssen the share price has been depressed. The company is however making progress with its projects and now has three clinical projects in phase 1, two of which are getting ready for phase 2. Read the complete analysis here.